Our study provides a rationale for further preclinical and clinical investigations of anti-ROR1 mAbs and their derivatives in the treatment of high risk and chemorefractory pediatric B-ALL in an attempt to improve relapse-free survival rates and overcome short-term and long-term toxicities associated with current treatment regimens. Here, ROR1 is linked to precursor B-cell acute lymphoblastic leukemia.